Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform
Yu‐Qing Zhang(Soochow University), Thanh U. Barbie(Brigham and Women's Hospital), Kara M. Soroko(Dana-Farber Cancer Institute), Sophie Kivlehan(Dana-Farber Cancer Institute), Elliott J. Brea(Dana-Farber Cancer Institute), Cloud P. Paweletz(Massachusetts General Hospital), Caroline Fahey(Dana-Farber Cancer Institute), Tran C. Thai(Dana-Farber Cancer Institute), David A. Barbie(Dana-Farber Cancer Institute), Jessica Ritter(Dana-Farber Brigham Cancer Center), Deborah Dillon(Harvard University), Koji Haratani(Dana-Farber Cancer Institute), Sung-Rye Park(Dana-Farber Cancer Institute), Eric Minwei Liu(Columbia University Irving Medical Center), Elena V. Ivanova(Massachusetts General Hospital), Patrick H. Lizotte(Harvard University), Prafulla C. Gokhale(Harvard University), Navin R. Mahadevan(Brigham and Women's Hospital), Eric L. Smith(Dana-Farber Cancer Institute), Michael Tolstorukov(Dana-Farber Cancer Institute), William E McGourty(Dana-Farber Cancer Institute), Zehua Li(Dana-Farber Cancer Institute)
Cited by 4